ClinicalTrials.gg
CompletedNCT01738035NEFIGANUpdated Sep 24, 2015

The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

A Phase 2 interventional study of NEFECON and Placebo in Primary IgA Nephropathy, sponsored by Calliditas Therapeutics AB. Completed at 58 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-24.

Sponsored by Calliditas Therapeutics AB · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Glomerulonephritis, IGA with a site in Germany — 6 open to participants now, 12 under way, 10 of them phase 3. Glomerulonephritis, IGA · Germany.

Enrollment
14th of 26
150 · median 255
Started
2012
the only one that year
Phase 2
8 of 30
2 open now
Registered
3rd of 30
by date
Lead sponsor
3 of 30
Calliditas Therapeutics AB

Among the 30 studies in Glomerulonephritis, IGA with a site in Germany, this one is the 14th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 8 in phase 2, and was the 3rd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

6 of the 30 studies in Glomerulonephritis, IGA with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Glomerulonephritis, IGA with a site in Germany, or all of them as a file.
02

Study summary

The objective of the study is to evaluate efficacy and safety of two different doses of NEFECON in the treatment of patients with primary IgA nephropathy (IgAN) at risk of developing end-stage renal disease, under rigorous blood pressure control with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin II receptor I blocker (ARB).

Read the detailed description

NEFECON is an add-on treatment to other medications for nephropathy symptoms and kidney function, including ACEI and/or ARBs. Rigorous blood pressure control will be achieved over a 6-month Run-in Phase in which ACEI and/or ARB will be dosed to target a blood pressure of \<130/80 mm Hg and UPCR \<0.5 g/g. Patients who complete the Run-in Phase, and despite optimized ACEI and/or ARB therapy, have a UPCR ≥0.5 g/g OR urine protein ≥0.75 g/24hr will be eligible for randomization and entry into the treatment phase of the trial. Patients will remain on their ACEI and/or ARB dosing regimen for the duration of the trial.

Patients entering the treatment phase will be administered NEFECON (8 mg/day OR 16 mg/day) OR placebo for a phase of 9 months. A 3-month follow-up phase will follow on from the treatment phase, of which the first 2 weeks will be used to taper the dose of those patients that received 16 mg/day dosing to 8 mg/day, with the placebo and 8 mg/day groups receiving placebo to retain blinding.

03

Conditions studied

  • Primary IgA Nephropathy

Keywords

  • IgA nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Screening Inclusion Criteria:

  1. Female or male patients ≥18 years
  2. -verified IgA nephropathy
  3. Urine protein creatinine ratio ≥0.5 g/g OR urine protein ≥0.75 g/24hr
  4. Estimated (using the CKD-EPI formula) OR measured GFR ≥50 mL/min per 1.73 m2 OR ≥45 mL/min per 1.73m2 for patients on a maximum recommended or maximum tolerated dose of an ACEI and/or ARB
  5. Willing to change antihypertensive medication regimen if applicable
  6. Willing and able to give

Screening Exclusion Criteria:

  1. Secondary forms of IgA nephropathy as defined by the treating physician (for example, Henoch-Schönlein purpura patients and those with associated alcoholic cirrhosis)
  2. Presence of crescent formation in ≥50% of glomeruli assessed on renal biopsy
  3. Kidney transplanted patients 4. Severe gastrointestinal disorders (including peptic ulcer disease and inflammatory bowel disease) which may impair drug effect, or other conditions which could modify the effect of the trial drug as judged by the Investigator
  4. Patients currently treated with systemic or systemic drugs (excluding topical or nasal steroids) or have been previously treated for more than one week within the last 24 months.
  5. Patients currently treated chronically (daily dosing) with inhaled corticosteroid drugs or have previously been treated chronically for more than one month within the last 12 months
  6. Patients previously treated with immunosuppressive or systemic corticosteroids for the treatment of IgA nephropathy
  7. Patients unable to take oral medication or intolerant to budesonide or other corticosteroid preparations
  8. Patients with known allergy or intolerance to ACEI, ARB or to any component of the trial drug formulation
  9. Patients with acute or chronic infectious disease incl. hepatitis, positive patients and patients with chronic urinary tract infections
  10. Severe liver disease according to the discretion of the Investigator
  11. Patients with Type 1 or 2 diabetes
  12. Patients with uncontrolled cardiovascular disease as judged by the Investigator
  13. Patients with current or history of malignancy during the last three years
  14. For women only; pregnant or breast feeding or unwilling to use adequate during the trial (only women of child bearing potential)

Randomization Inclusion Criteria:

  1. Completion of the Run-in Phase
  2. Urine protein creatinine ratio ≥0.5 g/g OR urine protein ≥0.75 g/24hr
  3. eGFR ≥45 mL/min per 1.73 m2 using CKD-EPI formula OR measured GFR ≥45 mL/min per 1.73 m2

Randomization Exclusion Criteria:

  1. Unacceptable blood pressure defined as a systolic value >160 mm Hg or diastolic >100 mm Hg
  2. eGFR (CKD-EPI) loss >30% over the entire duration of the Run-in Phase
  3. For women only; pregnant or breast feeding or unwilling to use adequate contraception during the trial (only women of child bearing potential)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    NEFECON 8 mg/day

    NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months

    Drug: NEFECON

  • Experimental
    NEFECON 16 mg/day

    NEFECON 16 mg/day (4 active capsules daily) for 9 months

    Drug: NEFECON

  • Placebo comparator
    Placebo

    Placebo (4 placebo capsules daily) for 9 months

    Other: Placebo

Interventions

  • All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.

    Also known as: Budesonide modified-released capsules (4 mg/capsule)

  • OtherPlacebo

    All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.

06

What researchers measure

Primary outcomes

  1. Change from baseline in urine protein creatinine ratio

    Time frame: 9 months

Secondary outcomes

  1. Change from baseline in urine albumin creatinine ratio

    Time frame: 9 months

  2. Change from baseline in 24 hour albuminuria

    Time frame: 9 months

  3. Change from baseline in estimated GFR

    Time frame: 9 months

Other outcomes

  1. Change from baseline in urine protein creatinine ratio

    Time frame: 3-12 months

  2. Change in urine albumin creatinine ratio

    Time frame: 3-12 months

  3. Change from baseline in 24 hour albuminuria

    Time frame: 3-12 months

  4. Change from baseline in estimated GFR

    Time frame: 3-12 months

07

Study locations

58 sites
  • University Hospital of Antwerp
    Antwerp, Belgium
  • Imelda Hospital
    Bonheiden, Belgium
  • Ghent University Hospital
    Ghent, Belgium
  • University Hospitals Leuven
    Leuven, Belgium
  • Heilig Hartziekenhuis Roeselare-Menen
    Roeselare, Belgium
  • University Hospital
    Olomouc, Czech Republic
  • Charles University & General University Hospital
    Prague, Czech Republic
  • Institut klinické a experimentální medicíny
    Prague, Czech Republic
  • Rigshospitalet
    Copenhagen, Denmark
  • Herlev Hospital
    Herlev, Denmark
  • Odense University Hospital
    Odense, Denmark
  • Helsinki University Central Hospital
    Helsinki, Finland
  • Tampere University Hospital
    Tampere, Finland
  • Turku University Central Hospital
    Turku, Finland
  • RWTH Aachen
    Aachen, Germany
  • Klinikum Augsburg
    Augsburg, Germany
  • Charité Hospital
    Berlin, Germany
  • Charité-Virchow Clinic
    Berlin, Germany
  • Vivantes Klinikum im Friedrichshain
    Berlin, Germany
  • Klinikum-Bremen-Mitte
    Bremen, Germany
  • University Hospital Carl Gustav Carus
    Dresden, Germany
  • Studienzentrum Karlstrasse
    Düsseldorf, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Germany
  • Universitätsmedizin Göttingen
    Göttingen, Germany
  • University Hospital
    Heidelberg, Germany
  • University of Jena
    Jena, Germany
  • Universitätsklinikum Magdeburg
    Magdeburg, Germany
  • Universität München
    Munich, Germany
  • Universitätsklinikum Münster
    Münster, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Germany
  • Deutsche Klinik für Diagnostik
    Wiesbaden, Germany
  • Würzburg University Hospital
    Würzburg, Germany
  • Policlinico di Bari
    Bari, Italy
  • Azienda Ospedaliera G. Brotzu
    Cagliari, Italy
  • Ospedale A Manzoni
    Lecco, Italy
  • Bassini Hospital
    Milano, Italy
  • Ospedale S. G. Bosco
    Torino, Italy
  • Belcolle Hospital
    Viterbo, Italy
  • University Medical Center
    Leiden, Netherlands
  • Fundación Puigver
    Barcellona, Spain
  • Hospital Universitario Vall d'Hebron
    Barcellona, Spain
  • 12 de Octubre Hospital
    Madrid, Spain
  • Fundación Jimenez Diaz Hospital
    Madrid, Spain
  • Hospital Universitario Gregorio Marañon
    Madrid, Spain
  • Central sjukhuset
    Karlstad, Sweden
  • Karlstad Central Hospital
    Karlstad, Sweden
  • University Hospital
    Linköping, Sweden
  • Danderyds Hospital
    Stockholm, Sweden
  • Karolinska University Hospital
    Stockholm, Sweden
  • Uppsala University Hospital
    Uppsala, Sweden
  • Belfast City Hospital
    Belfast, United Kingdom
  • Ulster Hospital
    Belfast, United Kingdom
  • Royal Derby Hospital
    Derby, United Kingdom
  • Edinburgh Royal Infirmary
    Edinburgh, United Kingdom
  • Western Infirmary
    Glasgow, United Kingdom
  • The Leeds Teaching Hospitals NHS Trust
    Leeds, United Kingdom
  • Leicester General Hospital
    Leicester, United Kingdom
  • James Cook University Hospital
    Middlesbrough, United Kingdom
08

References and documents

Publications

  • Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sorensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28. PubMed 28363480 ↗
  • Yeo SC, Liew A, Barratt J. Emerging therapies in immunoglobulin A nephropathy. Nephrology (Carlton). 2015 Nov;20(11):788-800. doi: 10.1111/nep.12527. PubMed 26032537 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Jun 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2012
First posted
Nov 30, 2012
Start
Dec 2012
Primary completionActual
Jun 2015
CompletionActual
Sep 2015
Last update
Sep 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01738035
Lead sponsor
Calliditas Therapeutics AB
Responsible party
Sponsor
First posted
Nov 30, 2012
Start date
Dec 2012
Primary completion
Jun 2015
Completion
Sep 2015
Last update
Sep 24, 2015

Study contacts

Bengt Fellström, MD, PhD
principal investigator · Professor of Medicine Department of Medical Sciences, Renal Medicine Uppsala University Hospital, Sweden
Alex Mercer, PhD
study director · Pharmalink AB, Stockholm, Sweden

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion